Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.

Journal: BMC cancer

PMID: 40340824

Abstract

BACKGROUND: CDK4/6 inhibitors plus aromatase inhibitors (AI) significantly improve the therapeutic effect of initial treatment for HR + /HER2- advanced breast cancer. However, there is a lack of head-to-head randomized controlled trials involving the four CDK4/6 inhibitors in current clinical treatments. This article aims to compare the efficacy and safety of the four CDK4/6 inhibitors in previously untreated HR + /HER2- advanced breast cancer for a better clinical medication selection.

Authors

Yanrong Kang

Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong, 264001, China.
Bing Han

Harbin University of Commerce, Harbin, China.
Yongmei Kong

Department of Body Radiotherapy, Shandong Second Province General Hospital, Jinan, Shandong, 250021, China.
Shuai Liu

Graduate School of Chinese Academy of Traditional Chinese Medicine, Beijing, China.
Nan Zhang

Department of Pulmonary and Critical Care Medicine II, Emergency General Hospital, Beijing, China.

Keywords

Aminopyridines Antineoplastic Combined Chemotherapy Protocols Aromatase Inhibitors Benzimidazoles Breast Neoplasms Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Female Humans Network Meta-Analysis as Topic Progression-Free Survival Protein Kinase Inhibitors Purines Randomized Controlled Trials as Topic Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Treatment Outcome

External Resources

View on PubMed Access via DOI PubMed (40340824)

Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals